LB Pharmaceuticals 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, everybody, and welcome back at our third Guggenheim Healthcare Innovation Conference. I am Delma Caiati, and I am one of the analysts here at Guggenheim, and it is my pleasure to welcome next LB Pharmaceuticals here with us. From the company, we have Gad Soffer, the Chief Operating and Business Officer. It is my pleasure to have you here, Gad, and to have this conversation with you. This is such an exciting time for the company, of course. We have a lot to discuss, but before we go into the Q&A, I would like you to take the stage and maybe give us an overview of where you stand now, what investors should be looking for over the next 12, 24 months. Why do not we start there?
Excellent. Delma, thank you very much for the invitation. It is a pleasure to be here, and thank you all for coming to learn more about LB Pharmaceuticals. You are right, it is very much an exciting time here at LB. Our vision at LB is very clear. Our goal is to build a fully integrated neuromedicines company, one that is both capable and ready to commercialize innovative therapeutics that have the potential to really improve the ability for patients to fully live their life. As we say this internally, it is to live boldly. Our lead program, LB-102, is really a foundational asset. It is one that stands on the shoulders of decades of clinical and real-world validation from one of the most successful antipsychotics outside the U.S.
Earlier last year, we read out data from our NOVA 1 study in schizophrenia that had highly statistically significant results across all the doses and suggested the opportunity for a really differentiated profile in what we know is a very large branded antipsychotic market. Coming out of conversations with FDA, we believe we have a path to registration with just a single additional phase III study. The mechanism of the drug is also broad, so it provides opportunity to expand both in psychosis as well as in mood disorders, as I know we will talk about. We have a strong IP portfolio with compositions covering to the early 2040s, including patent term extension, and a really strong balance sheet. That balance sheet enables us to fund our ongoing phase III NOVA 2 trial, which we expect to read out in the first half of 2027.
It also supports the ongoing open-label safety trial, as well as the NDA enabling studies, all the things that we need to do to put ourselves in position to support an approval of a new chemical entity. We are also running a phase II bipolar depression study, which started earlier this year and should read out in the first quarter of 2028. In addition, we expect to start an MDD phase II trial early next year, which will read out in the first half of 2029. Stepping back, the capital base that we have today really puts us in a position to have a very meaningful set of significant clinical milestones across very large diseases with significant unmet need, starting in 2027 with schizophrenia, 2028 bipolar depression, 2029 MDD.
Thank you for that great overview, and clearly a lot of things going on in the company. Let's take a step back. As you said, LB-102 is the first benzamide to be developed in the U.S. amisulpride, which has a similar structure, is already approved ex-U.S., and is one of the most efficacious antipsychotics. So why was amisulpride never developed in the U.S.? Why was it never brought here, and how did you make a new molecular entity out of that?
Yeah. amisulpride was originally developed by a company called Synthélabo. It got its initial approval in France in the late 1980s and then expanded to other European geographies from there. You're right, it is a very well-regarded therapeutic, second highest effect size, only to clozapine, very low all-cause discontinuation rate. Sanofi purchased Synthélabo in the late 1990s, and they tried to bring amisulpride to the United States. Unfortunately, they were asked to do an entirely new clinical development program, and they simply didn't have the requisite IP life remaining on the drug, and so they chose not to do that. Although amisulpride is a very successful drug, it's approved in schizophrenia, negative symptoms of schizophrenia, dysthymia, it does have a couple of significant limitations.
It has very poor blood-brain barrier permeability, and as a consequence, it needs to be delivered at very high doses, and it needs to be administered twice daily. LB Pharmaceuticals set out to retain the benefits of amisulpride. It is a very unique D2 antagonist, very selective for D2, D3, five-HT7, but do it in a way that we could also solve those limitations. We did that by methylating the drug. That methylation improved the lipophilicity of the molecule, and improved the ability to permeate the brain, resulting in a molecule that was more potent.
50 milligrams of LB-102 is the equivalent of about 400 milligrams of amisulpride. Both of those doses have about 70% receptor occupancy. It also enabled us to dose QD because we have a little bit of a longer residence time in the CNS. As we saw in our NOVA 1 trial, potentially an even better tolerability profile than that of amisulpride.
Following up on the tolerability side in particular. We know that schizophrenia is obviously a challenging market in a way, where differentiation matters. What are the key differentiating features of LB-102, as you saw from the phase II trial and based on what we know also from amisulpride, and which one really matters when you think about the commercial perspective?
Yeah. I think schizophrenia is a disease where, first and foremost, physicians need to know that you have a drug that can control the positive symptoms. But beyond, that's sort of the entry ticket. Beyond that, as you said, tolerability is centrally important because these patients need to stay on these drugs chronically, and every time a patient relapses, they do irreparable harm to themselves. So the profile that we generated in NOVA 1, we think demonstrates that very competitive efficacy, effect sizes near the top of approved antipsychotics, with a tolerability profile that we see as class-leading among the D2 antagonists and partial agonists, specifically as it relates to extrapyramidal symptoms, which are these movement disorders that often come along with D2 antagonists, as well as sedation, which can be a very challenging side effect for many of these patients.
The other element of having, I think, a successful therapy in schizophrenia is simplicity of use. Adherence is so important. Speed of onset is important. So having a drug with no titration, that you can start at a therapeutic dose immediately, that's QD with no food effect, few drug-drug interactions, that's really important. So those are really the key elements. Then, being able to address the residual symptoms that are also significant unmet needs in schizophrenia, like negative symptoms, like cognitive impairment, those are upsides. But the core is competitive efficacy, tolerability to sustain use, and simplicity of dosing.
Low EPS, as you were saying, is a particularly interesting feature of the drug, because if we consider all the other D2 agents, they are all producing high level of extrapyramidal symptoms. So from a scientific perspective, how can that be explained? What have you seen preclinically and also based on the mechanism that justifies that differentiation?
Yeah. It is a really striking finding. The NOVA 1 trial tested doses between 50 and 100 milligrams of LB-102, which equate to receptor occupancies of 70%-80%. In that range, you would expect to see more EPS. What we saw was really striking. At our 50-milligram dose, we had just a single case of akathisia, less than 1% EPS rate. At our 100-milligram dose, even when we were pushing slightly above 80% receptor occupancy, we just had 5.6% EPS compared to 3.7% placebo. So really, really low. One of the things, there's a lot of literature on amisulpride focusing on regional selectivity in the CNS. At our R&D Day a couple of weeks ago, we presented some data where we specifically looked at the relative activation profile of LB-102, amisulpride, and various other antipsychotics, in the motor versus the associative part of the striatum.
Ideally, what you want to do in schizophrenia is suppress dopamine signaling in the associative portion of the striatum and not affect the motor to avoid EPS. We were really encouraged to see in those results, which a preclinical study, of course, but really encouraged to see that LB-102 is really selective for the associative part of the striatum. I think the import of that finding is that it provides a plausible potential mechanism for why it is that we're seeing such low rates of EPS, despite the high receptor occupancy.
Yeah. That makes sense, and it's clearly supportive. Now, looking forward to the phase III that is ongoing, you will have data in the first half of next year. Of course, as we know, in schizophrenia, managing placebo is always challenging, and you have mirrored basically with NOVA 2 what you did with the NOVA 1 trial. There are a few changes there. How do you expect those changes to affect placebo, and how are you controlling for that?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
